INKT Stock Analysis: Buy, Sell, or Hold?
INKT - MiNK Therapeutics, Inc. Common Stock
$10.79
0.10 (0.94%)
▲
5d:
+2.37%
30d:
-6.66%
90d:
-6.98%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When INKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: INKT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: INKT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: INKT is currently trading at $10.79, which is considered fair relative to its 30-day fair value range of $10.51 to $11.44.
Technical Outlook: Technically, INKT is showing sideways momentum. Immediate support is located at $10.21, while resistance sits at $11.30.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.00 (+264.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INKT is showing sideways momentum. Immediate support is located at $10.21, while resistance sits at $11.30.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.00 (+264.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.51 -
$11.44
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 264.8% below Wall St target ($39.00)
Trading Range Analysis
30-Day Trading Range
$10.51 -
$11.44
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.21
Resistance Level
$11.30
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.74
Wall Street Target
$39.00
(+264.8%)
Share & Embed Analysis
Last updated: August 04, 2026 11:11 AM ET
Data refreshes hourly during market hours. Next update: 12:11 PM
Data refreshes hourly during market hours. Next update: 12:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara Ryan
SELL
1300 shares
2026-03-10
Barbara Ryan
SELL
200 shares
2026-03-09
Barbara Ryan
SELL
100 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
